Journal of the American Society of Hypertension
Volume 2, Issue 4, Supplement , Pages S1-S2 , July 2008

Introduction

References 

  1. Mancia G, Facchetti R, Bombelli M, Friz HP, Grassi G, Giannattasio C, et al. Relationship of office, home, and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. Hypertension. 2005;45:1072–1077
  2. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527–1535
  3. Sharma AM, Davidson J, Koval S, Lacourciere Y SMOOTH Study Investigators. Telmisartan/HCTZ versus valsartan/HCTZ in obese hypertensive patients with type 2 diabetes: the SMOOTH Study. Cardiovasc Diabetol. 2007;6:28
  4. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860
  5. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869
  6. Bakris G, Burgess E, Davidai G, Koval S, Weir M; the AMADEO Investigators. Influence of glycemic control on proteinuria in patients with type 2 diabetes and overt nephropathy and hypertension: results of the AMADEO trial. A poster presented at the 67th Scientific Sessions of the American Diabetes Association, Chicago, Illinois, June 22–26, 2007.
  7. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995–1003
  8. Sleight P. The ONTARGET/TRANSCEND Trial Programme: baseline data. Acta Diabetol. 2005;42:S50–S56
  9. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment study in ACE INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J. 2004;148:52–61

PII: S1933-1711(08)00037-5

doi: 10.1016/j.jash.2008.03.005

Journal of the American Society of Hypertension
Volume 2, Issue 4, Supplement , Pages S1-S2 , July 2008

Article Tools